Triple-drug therapy for recurrent ovarian clear cell cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of three drugs—liposomal irinotecan (chemotherapy), sintilimab (immunotherapy), and anlotinib (targeted therapy)—for people with recurrent or persistent ovarian clear cell carcinoma who have already tried platinum-based chemotherapy. The goal is to see if this triple therapy can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with recurrent or persistent ovarian clear cell carcinoma.
- You must have already received at least one round of platinum-based chemotherapy.
- You must be between 18 and 75 years old.
- Your cancer must be measurable by scans (like CT or MRI), with tumors at least 1 cm in size.
- You cannot have had prior treatment with immune checkpoint inhibitors (like PD-1 or CTLA-4 blockers).
- You must not have active autoimmune disease, brain metastases needing surgery, or other serious uncontrolled health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and a low-dose chemo) for people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It aims to find a new option when standard platinum chemo no longer works or cannot be used.
This trial tests a combination of two drugs—dostarlimab (an immunotherapy) and LB-100 (a new drug targeting a protein called PP2A)—for people with clear cell ovarian cancer that has returned or is resistant to platinum chemotherapy. The goal is to see if this combination is safe and effective for this specific type of cancer.
This trial tests a new combination therapy (SYS6041 plus another drug) for women with recurrent ovarian cancer. It is for those whose cancer has come back after platinum chemotherapy, and who have not had too many previous treatments. The goal is to see if the combination can shrink tumors or slow disease progression.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.